STATE OF NEVADA

BOARD OF PHARMACY

985 Damonte Ranch Pkwy, Ste 206
Reno, NV 89521

Posted: August 31, 2022

NOTICE OF INTENT TO ACT UPON A REGULATION

Notice of Hearing for the Adoption and Amendment of
Regulations of the Nevada State Board of Pharmacy

The Nevada State Board of Pharmacy will hold a Public Hearing at 9:00 a.m. on Thursday, October 13, 2022.

Pursuant to NRS 241.023(1)(c) the meeting is being conducted by means of remote technology. The public may attend the meeting via live stream remotely or in person at the following location:

Hilton Garden Inn
7830 S Las Vegas Boulevard
Las Vegas, NV

Via Videoconference at Zoom: https://zoom.us/j/5886256671
or
Via Teleconference at 1 (669) 900-6833
Meeting ID: 588 625 6671

The purpose of the hearing is to receive comments from all interested persons regarding the adoption and amendment of regulations that pertain to Chapters 453 and/or 639 of the Nevada Administrative Code.

The following information is provided pursuant to the requirements of NRS 233B.060:

A. Amendment to Nevada Administrative Code (NAC) 639. The proposed amendments authorize who is registered with the Board to dispense controlled substances and practices in a hospital or independent center for emergency medical care to dispense a controlled substance that has been federally approved for the treatment of opioid use disorder without a certificate of registration to dispense controlled substances or dangerous drugs at the specific site where he or she practices. (LCB File R087-22)

1. The need for and the purpose of the proposed regulation or amendment.

A hospital emergency room is often the entry point and/or primary source of medical care for individuals with opioid use disorder (OUD). The proposed amendment reduces the barriers to medication treatment for people with OUD. Initiating treatment in an emergency room improves patient outcomes until they have the opportunity to enroll in a treatment program. Implementing these regulations will expand access to treatment for individuals with OUD.

2. Either the terms or the substance of the regulations to be adopted and amended.

A copy of the proposed regulation is attached to this notice.

3. The estimated economic effect of the regulation on the business which it is to regulate and on the public:

(a) Both adverse and beneficial effects.

There should be no adverse economic impact from these regulation amendments on the regulated entities or on the public. The beneficial effects will be expanded access to medical care for individuals with OUD.

(b) Both immediate and long-term effects.

Both the immediate and long-term economic effects on regulated entities and on the public will be beneficial by removing unnecessary barriers and providing expanded access to medical care for individuals with OUD.

4. The estimated cost to the agency for enforcement of the proposed regulation.

There will be no additional or special costs incurred by the Board of Pharmacy for enforcement of this regulation amendment.

5. A description of and citation to any regulations of other state or local governmental agencies which the proposed regulation overlaps or duplicates and a statement explaining why the duplication or overlapping is necessary. If the proposed regulation overlaps or duplicates a federal regulation, the notice must include the name of the regulating federal agency.

The Board of Pharmacy is not aware of any similar regulations of any other state or local governmental agency that the proposed regulation amendment overlaps or duplicates.

6. If the regulation is required pursuant to federal law, a citation and description of the federal law.

The regulation is not required by federal law.

7. If the regulation includes provisions which are more stringent than a federal regulation that regulates the same activity, a summary of such provisions.

The Board of Pharmacy is not aware of any similar federal regulation of the same activity in which the state regulation is more stringent.

8. Whether the proposed regulation establishes a new fee or increases an existing fee.

This regulation does not provide a new or increase of fees.

B. **Amendment to Nevada Administrative Code (NAC) 639**. The proposed amendments establish the requirements for a group of practitioners practicing at a reproductive healthcare center to obtain a certificate of registration from the State Board of Pharmacy to maintain a single inventory of certain dangerous drugs for dispensing at a site of practice. (LCB File R181-22)

1. The need for and the purpose of the proposed regulation or amendment.

The proposed amendments establish the definition of reproductive healthcare center and authorizes a group of practitioners practicing at a reproductive healthcare center to obtain a certificate of registration to maintain a single inventory of dangerous drugs received at a site of practice in lieu of maintaining separate inventories for each dispensing practitioner. The amendment provides cost effective inventory management for dispensing practitioners within a reproductive healthcare center and expanded access to reproductive health care for patients.

2. Either the terms or the substance of the regulations to be adopted and amended.

A copy of the proposed regulation amendment is attached to this notice.

3. The estimated economic effect of the regulation on the business which it is to regulate and on the public:

(a) Both adverse and beneficial effects.

There should be no adverse economic impact from this regulation amendment on the regulated entities or on the public. The regulation amendment will have a beneficial effect on the regulated entities by providing cost effective inventory management for dispensing practitioners within a reproductive healthcare center. The regulation amendment will have a beneficial effect on the public by expanding access to reproductive health care.

(b) Both immediate and long-term effects.

Both the immediate and long-term economic effects on regulated entities and on

the public will be beneficial since the amendment will improve the delivery of reproductive health care to patients by removing unnecessary barriers and provide cost effective inventory management for dispensing practitioners.

4. The estimated cost to the agency for enforcement of the proposed regulation.

There will be no additional or special costs incurred by the Board of Pharmacy for enforcement of this regulation amendment.

5. A description of and citation to any regulations of other state or local governmental agencies which the proposed regulation overlaps or duplicates and a statement explaining why the duplication or overlapping is necessary. If the proposed regulation overlaps or duplicates a federal regulation, the notice must include the name of the regulating federal agency.

The Board of Pharmacy is not aware of any similar regulations of any other state or local governmental agency that the proposed regulation amendment overlaps or duplicates.

6. If the regulation is required pursuant to federal law, a citation and description of the federal law.

This regulation is not required by federal law.

7. If the regulation includes provisions which are more stringent than a federal regulation that regulates the same activity, a summary of such provisions.

The Board of Pharmacy is not aware of any similar federal regulation amendments of the same activity in which the state regulation is more stringent.

8. Whether the proposed regulation establishes a new fee or increases an existing fee.

This regulation does not provide a new or increase of fees.

Persons wishing to comment upon the proposed action of the Board may appear at the scheduled public hearing or may address their comments, data, views, or arguments, in written form, to the Board at pharmacy@pharmacy.nv.gov or to the Nevada State Board of Pharmacy, 985 Damonte Ranch Parkway, Suite 206 – Reno, NV 89521. Written submissions must be received by the Board on or before October 12, 2022. If no person who is directly affected by the proposed action appears to request time to make an oral presentation, the Board may proceed immediately to act upon any written submissions.

Members of the public who are disabled and require special accommodations or assistance at the meeting are requested to notify the Nevada State Board of Pharmacy in writing at 985 Damonte Ranch Pkwy., #206, Reno, Nevada 89521, or by calling (775) 850-1440. Please notify us at least one (1) week prior to the scheduled meeting date to allow time to secure any necessary equipment or provisions prior to the meeting.

This notice and the text of the proposed regulation are also available in the State of Nevada Register of Administrative Regulations which is prepared and published monthly by the Legislative Counsel Bureau pursuant to NRS 233B.0653, and on the Internet at http://www.leg.state.nv.us. Copies of this notice and the proposed regulation will also be mailed to members of the public upon request.

Pursuant to NRS 233B.064(1), upon adoption of any regulation, the Board, if requested to do so by an interested person, either before adoption or within 30 days thereafter, will issue a concise statement of the principal reasons for and against its adoption, and incorporate therein its reason for overruling the consideration urged against its adoption.

This notice of hearing has been posted at the following locations:

Nevada State Board of Pharmacy
Reno, Nevada

Nevada State Board of Pharmacy
Las Vegas, Nevada

Mineral County Courthouse
Hawthorne, Nevada

Elko County Courthouse
Elko, Nevada

Washoe County Courthouse
Reno, Nevada

PROPOSED REGULATION OF THE

STATE BOARD OF PHARMACY

LCB File No. R087-22

August 8, 2022

EXPLANATION – Matter in *italics* is new; matter in brackets [~~omitted material~~] is material to be omitted

AUTHORITY: § 1, NRS 453.221 and 639.070; § 2, NRS 639.070.

A REGULATION relating to controlled substances; authorizing a practitioner to dispense certain controlled substances without a certificate of registration to dispense controlled substances or dangerous drugs at a specific site; requiring such a practitioner to comply with certain labeling, recordkeeping and reporting requirements; and providing other matters properly relating thereto.

Legislative Counsel's Digest:

Existing law authorizes the State Board of Pharmacy to adopt regulations relating to the registration and control of the dispensing of controlled substances. (NRS 453.221) Existing law requires every practitioner who dispenses a controlled substance to register with the Board. (NRS 453.226) Existing regulations further require a practitioner who dispenses controlled substances or dangerous drugs to obtain a certificate of registration for each site where he or she practices. (NAC 639.742) **Sections 1 and 2** of this regulation authorize a practitioner who is registered with the Board to dispense controlled substances and practices in a hospital or independent center for emergency medical care to dispense a controlled substance that has been federally approved for the treatment of opioid use disorder without a certificate of registration to dispense controlled substances or dangerous drugs at the specific site where he or she practices. **Section 1** requires such a practitioner to comply with: (1) certain federal regulations relating to prescribing a controlled substance; and (2) certain regulations concerning labeling, recordkeeping and reporting when a controlled substance is dispensed.

Section 1. Chapter 639 of NAC is hereby amended by adding thereto a new section to read as follows:

1. A practitioner who is practicing in a hospital or independent center for emergency medical care may dispense a controlled substance that has been approved by the United States Food and Drug Administration for the treatment of opioid use disorder without registering

pursuant to NAC 639.742 if the practitioner is registered to dispense controlled substances pursuant to NRS 453.226.

2. A practitioner who dispenses a controlled substance that has been approved by the United States Food and Drug Administration for the treatment of opioid use disorder shall comply with:

(a) 21 C.F.R. Parts 1306 and 1307;

(b) Any requirements concerning labeling or recordkeeping that apply to practitioners who are registered pursuant to NAC 639.742; and

(c) The requirements of NAC 639.926 concerning the transmission of information to the Board.

3. A pharmacist who is employed by a hospital or independent center for emergency medical care may assist a practitioner in the dispensing of the controlled substance pursuant to this section.

4. As used in this section, "independent center for emergency medical care" has the meaning ascribed to it in NRS 449.013.

Sec. 2. NAC 639.742 is hereby amended to read as follows:

639.742 1. Except as otherwise provided in NAC 639.7423 ~~[,]~~ *and section 1 of this regulation,* a practitioner who wishes to dispense controlled substances or dangerous drugs, or both, for human consumption must apply to the Board on an application provided by the Board for a certificate of registration to dispense controlled substances or dangerous drugs. A practitioner must submit a separate application for each site of practice, including, without limitation, a telepharmacy, remote site or satellite consultation site, from which the practitioner wishes to dispense controlled substances or dangerous drugs, or both, for human consumption. A

certificate of registration to dispense controlled substances or dangerous drugs, or both, for human consumption is a revocable privilege, and no holder of such a certificate of registration acquires any vested right therein or thereunder.

2. Except as otherwise provided in NAC 639.7423, section 3 of LCB File No. R004-19 ***and section 1 of this regulation,*** if a facility from which the practitioner intends to dispense dangerous drugs or controlled substances, or both, for human consumption is not wholly owned and operated by the practitioner, the owner or owners of the facility must also submit an application to the Board on a form provided by the Board.

3. Except as otherwise provided in NRS 639.23277 and NAC 639.395, 639.648 and 639.7423, the dispensing practitioner and, if applicable, the owner or owners of the facility and any federally-qualified health center vehicle, shall ensure that:

(a) All drugs are ordered by the dispensing practitioner;

(b) All drugs are received and accounted for by the dispensing practitioner;

(c) All drugs are stored in a secure, locked room or cabinet to which the dispensing practitioner has the only key or lock combination;

(d) All drugs are dispensed in accordance with NAC 639.745;

(e) No prescription is dispensed to a patient unless the dispensing practitioner is on-site at the facility or federally-qualified health center vehicle, as applicable;

(f) All drugs are dispensed only to the patient personally at the facility or federally-qualified health center vehicle, as applicable;

(g) The price of each drug dispensed to a patient is separately itemized on any bill or statement provided to the patient;

(h) All drugs are dispensed only for medically necessary purposes and according to prevailing standards of care for practitioners practicing in the specialty claimed or practiced by the dispensing practitioner; and

(i) The certificate for each dispensing technician employed at the facility is displayed in the room or cabinet in which drugs are stored.

4. Except as otherwise provided in NAC 639.648 and 639.7423, with regard to the filling and dispensing of a prescription at a facility, only the dispensing practitioner or a dispensing technician may:

(a) Enter the room or cabinet in which drugs are stored;

(b) Remove drugs from stock;

(c) Count, pour or reconstitute drugs;

(d) Place drugs into containers;

(e) Produce and affix appropriate labels to containers that contain or will contain drugs;

(f) Fill containers for later use in dispensing drugs; or

(g) Package or repackage drugs.

5. Except as otherwise provided in NAC 639.7423, a dispensing practitioner may compound drug products if he or she complies with the provisions of NAC 639.661 to 639.690, inclusive, as if:

(a) He or she were a pharmacist;

(b) His or her practice site was a pharmacy; and

(c) Any dispensing technician involved in the compounding was a pharmaceutical technician.

PROPOSED REGULATION OF THE

STATE BOARD OF PHARMACY

LCB File No. R181-22

August 29, 2022

EXPLANATION – Matter in *italics* is new; matter in brackets [~~omitted material~~] is material to be omitted.

AUTHORITY: §§ 1-3, NRS 639.070.

A REGULATION relating to pharmacy; establishing the requirements for a group of practitioners practicing at a reproductive healthcare center to obtain a certificate of registration from the State Board of Pharmacy to maintain a single inventory of dangerous drugs received at a site of practice; prescribing certain powers and duties of dispensing practitioners of a registered group of practitioners practicing at a reproductive healthcare center; and providing other matters properly relating thereto.

Legislative Counsel's Digest:

Existing law authorizes an exclusive list of persons, including practitioners, to possess and administer a dangerous drug in this State. (NRS 454.213) Existing law authorizes the State Board of Pharmacy to adopt regulations governing the dispensing of poisons, drugs, chemicals and medicines. (NRS 639.070) Existing regulations require a practitioner who wishes to dispense dangerous drugs to obtain a certificate of registration from the Board and require the practitioner who is registered with the Board to perform certain duties relating to the dispensing dangerous of drugs. (NAC 639.742, 639.745)

Existing regulations authorize an oncology group practice to maintain a single inventory of dangerous drugs received at a site of practice in lieu of maintaining separate inventories for each dispensing practitioner of the oncology group practice if the oncology group practice applies to the Board for a certificate of registration and submits the applicable fee. The certificate: (1) entitles the oncology group practice to maintain a single inventory of dangerous drug at the site of the oncology group practice; and (2) is a revocable privilege. Existing regulations additionally prescribe the procedure for renewing such a certificate and requires an oncology group practice registered with the Board to notify the Board of the addition or removal of a dispensing practitioner of the practice. Existing regulations: (1) authorize a dispensing practitioner of an oncology group practice registered with the Board to maintain a single inventory of dangerous drugs at the site of the oncology group practice; and (2) requires such a dispensing practitioner to maintain separate records of each dangerous drug dispensed by him or her. (Section 1 of Adopted Reg. of the State Bd. of Pharm., LCB File No. R007-21)

Section 3 of this regulation similarly authorizes a group of practitioners practicing at a reproductive healthcare center to obtain a certification of registration authorizing: (1) the group to maintain a single inventory of dangerous drugs received at a site of practice; and (2) a

dispensing practitioner who is a member of the group to dispense any dangerous drug accounted for in the inventory of the group. **Section 3** prescribes: (1) the same procedure for the issuance and renewal of such a certificate as that for a certificate for an oncology group practice; and (2) similar authority and duties for a registered group of practitioners practicing at a reproductive health center as currently apply to an oncology group practice. **Section 1** of this regulation defines the term "reproductive healthcare center."

Finally, existing regulations provide that the dispensing practitioners of an oncology group practice registered with the Board are jointly responsible for ensuring compliance with certain requirements relating to the dispensing of dangerous drugs. (NAC 639.742) **Section 2** of this regulation similarly provides that a group of practitioners practicing at a reproductive healthcare center is jointly responsible for ensuring compliance with such requirements.

Sec. 1. NAC 639.010 is hereby amended to read as follows:

As used in this chapter, unless the context otherwise requires:

1. "Board" means the State Board of Pharmacy.

2. "Controlled substances" has the meaning ascribed to it in NRS 0.031.

3. "Dangerous drug" has the meaning ascribed to it in NRS 454.201.

4. "Direct supervision" means the direction given by a supervising pharmacist who is:

(a) On the premises of the pharmacy or telepharmacy at all times when the person he or she is supervising is working at the pharmacy or telepharmacy or at a remote site or satellite consultation site; and

(b) Aware of the activities of that person related to the preparation and dispensing of medications, including the maintenance of appropriate records.

5. "Dispensing practitioner" means:

(a) A practitioner to whom the Board has issued a certificate of registration pursuant to NAC 639.742 to dispense controlled substances or dangerous drugs, or both, for human consumption; or

(b) A licensed veterinarian to whom the Board has issued a certificate of registration pursuant to NAC 639.7423 to dispense controlled substances or dangerous drugs, or both, not for human consumption.

6. "Executive Secretary" means the Executive Secretary employed by the Board pursuant to NRS 639.040.

7. "Federally-qualified health center "has the meaning ascribed to it in 42 U.S.C. § 1396d(l)(2)(B).

8. "Federally-qualified health center vehicle" means a vehicle that meets the requirements of paragraph (c) of subsection 1 of section 3 of LCB File No. R004-19.

9. "Licensed veterinarian" has the meaning ascribed to it in NRS 638.007.

10. "Oncology group practice" means two or more dispensing practitioners who practice oncology in a group practice.

11. "Pharmaceutical technician" means a person who performs technical services in a pharmacy under the direct supervision of a pharmacist and is registered with the Board pursuant to NAC 639.240.

12. "Pharmaceutical technician in training" means a person who is registered with the Board pursuant to NAC 639.242 in order to obtain the training and experience required to be a pharmaceutical technician pursuant to subparagraph (3) of paragraph (d) of subsection 2 of NAC 639.240, or who is enrolled in a program of training for pharmaceutical technicians that is approved by the Board.

13. "Practitioner" has the meaning ascribed to it in NRS 639.0125.

14. "Prescription drug" means a drug or medicine as defined in NRS 639.007 which:

(a) May be dispensed only upon a prescription order that is issued by a practitioner; and

(b) Is labeled with the symbol "Rx only" pursuant to federal law or regulation.

15. "Public or nonprofit agency" means a health center as defined in 42 U.S.C. § 254b(a) which:

(a) Provides health care primarily to medically underserved persons in a community;

(b) Is receiving a grant issued pursuant to 42 U.S.C. § 254b or, although qualified to receive such a grant directly from the Federal Government, is receiving money from such a grant under a contract with the recipient of that grant; and

(c) Is not a medical facility as defined in NRS 449.0151.

16. ***"Reproductive healthcare center" means a health facility owned and operated by a nonprofit corporation or a public health center, as defined in subsection 8 of NRS 449.260, principally engaged in providing family planning services and reproductive healthcare, including, without limitation, the testing, diagnosis and treatment of, or providing of medication to prevent, a sexually transmitted infection or other infection of the urogenital system.***

17. "Surgical center for ambulatory patients" has the meaning ascribed to it in NRS 449.019.

Sec. 2. NAC 639.742 is hereby amended to read as follows:

639.742 1. Except as otherwise provided in NAC 639.7423, a practitioner who wishes to dispense controlled substances or dangerous drugs, or both, for human consumption must apply to the Board on an application provided by the Board for a certificate of registration to dispense controlled substances or dangerous drugs. A practitioner must submit a separate application for each site of practice, including, without limitation, a telepharmacy, remote site or satellite consultation site, from which the practitioner wishes to dispense controlled substances or

dangerous drugs, or both, for human consumption. A certificate of registration to dispense controlled substances or dangerous drugs, or both, for human consumption is a revocable privilege, and no holder of such a certificate of registration acquires any vested right therein or thereunder.

2. Except as otherwise provided in NAC 639.7423 and section 3 of LCB File No. R004-19, if a facility from which the practitioner intends to dispense dangerous drugs or controlled substances, or both, for human consumption is not wholly owned and operated by the practitioner, the owner or owners of the facility must also submit an application to the Board on a form provided by the Board.

3. Except as otherwise provided in this section and NRS 639.23277 and NAC 639.395, 639.648 and 639.7423, the dispensing practitioner and, if applicable, the owner or owners of the facility and any federally-qualified health center vehicle, shall ensure that:

(a) All drugs are ordered by the dispensing practitioner;

(b) All drugs are received and accounted for by the dispensing practitioner;

(c) All drugs are stored in a secure, locked room or cabinet to which the dispensing practitioner has the only key or lock combination;

(d) All drugs are dispensed in accordance with NAC 639.745;

(e) No prescription is dispensed to a patient unless the dispensing practitioner is on-site at the facility or federally-qualified health center vehicle, as applicable;

(f) All drugs are dispensed only to the patient personally at the facility or federally-qualified health center vehicle, as applicable;

(g) The price of each drug dispensed to a patient is separately itemized on any bill or statement provided to the patient;

(h) All drugs are dispensed only for medically necessary purposes and according to prevailing standards of care for practitioners practicing in the specialty claimed or practiced by the dispensing practitioner; and

(i) The certificate for each dispensing technician employed at the facility is displayed in the room or cabinet in which drugs are stored.

4. Except as otherwise provided in NAC 639.648 and 639.7423, with regard to the filling and dispensing of a prescription at a facility, only the dispensing practitioner or a dispensing technician may:

(a) Enter the room or cabinet in which drugs are stored;

(b) Remove drugs from stock;

(c) Count, pour or reconstitute drugs;

(d) Place drugs into containers;

(e) Produce and affix appropriate labels to containers that contain or will contain drugs;

(f) Fill containers for later use in dispensing drugs; or

(g) Package or repackage drugs.

5. Except as otherwise provided in NAC 639.7423, a dispensing practitioner may compound drug products if he or she complies with the provisions of NAC 639.661 to 639.690, inclusive, as if:

(a) He or she were a pharmacist;

(b) His or her practice site was a pharmacy; and

(c) Any dispensing technician involved in the compounding was a pharmaceutical technician.

6. Except as otherwise provided in subsection 6 of section 1 of LCB File No. R007-21, the dispensing practitioners of an oncology group practice ***or a group of practitioners practicing at***

a reproductive healthcare center registered pursuant to section 1 of LCB File No. R007-21 are jointly responsible for ensuring that the requirements of subsection 3 are met.

Sec. 3. Section 1 of LCB File No. R007-21 is hereby amended to read as follows:

1. An oncology group practice ***or a group of practitioners practicing at a reproductive healthcare center*** that wishes to maintain a single inventory of dangerous drugs, excluding compounded drug products, received at a site of practice in lieu of maintaining separate inventories for each dispensing practitioner of the oncology group practice ***or group of practitioners practicing at a reproductive healthcare center, as applicable,*** must apply to the Board on an application provided by the Board for a certificate of registration and submit the fee prescribed in NAC 639.220 for authorization of a practitioner, other than a licensed veterinarian, to dispense dangerous drugs. An oncology group practice ***or group of practitioners practicing at a reproductive healthcare center*** must submit a separate application and fee for each site of practice at which the oncology group practice ***or group of practitioners practicing at a reproductive healthcare center, as applicable,*** wishes to maintain a single inventory of dangerous drugs, excluding compounded drug products.

2. Upon receipt of a fee and approval of an application, the Board will issue a certificate of registration to an oncology group practice ~~,~~ ***or group of practitioners practicing at a reproductive healthcare center, as applicable.***

3. To renew a certificate of registration, an oncology group practice ***or group of practitioners practicing at a reproductive healthcare center*** must submit to the Board another completed application and the fee prescribed in NAC 639.220 for biennial renewal of authorization of a practitioner, other than a licensed veterinarian, to dispense dangerous drugs.

4. A certificate of registration issued pursuant to this section:

(a) Entitles the oncology group practice *or group of practitioners practicing at a reproductive healthcare center, as applicable,* to maintain a single inventory of dangerous drugs, excluding compounded drug products, at the site of practice for which the oncology group practice *or group of practitioners practicing at a reproductive healthcare center* received certification.

(b) Is a revocable privilege, and no holder of such a certificate of registration acquires any vested right therein or thereunder.

5. An oncology group practice *or group of practitioners practicing at a reproductive healthcare center* registered pursuant to this section shall provide written notice to the Board of the addition to or removal of a dispensing practitioner from the oncology group practice *or group of practitioners practicing at a reproductive healthcare center, as applicable,* not later than 15 days after the addition or removal, as applicable.

6. A dispensing practitioner of an oncology group practice *or group of practitioners practicing at a reproductive healthcare center* registered pursuant to this section:

(a) May dispense any dangerous drug accounted for in the single inventory of the oncology group practice ~~,~~ *or group of practitioners practicing at a reproductive healthcare center, as applicable.*

(b) Shall ensure that he or she complies with the requirements prescribed by NAC 639.745, including, without limitation, maintaining separate records of each dangerous drug dispensed by him or her.

7. As used in this section:

(a) "Compounded" has the meaning ascribed to "compound" and "compounding" in NAC 639.6625.

(b) "Drug product" has the meaning ascribed to it in NAC 639.6631.